Cargando…
Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
PURPOSE: The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974433/ https://www.ncbi.nlm.nih.gov/pubmed/34168047 http://dx.doi.org/10.1158/1078-0432.CCR-21-0529 |
_version_ | 1784680238188331008 |
---|---|
author | Marisa, Laetitia Blum, Yuna Taieb, Julien Ayadi, Mira Pilati, Camilla Le Malicot, Karine Lepage, Côme Salazar, Ramon Aust, Daniela Duval, Alex Blons, Hélène Taly, Valérie Gentien, David Rapinat, Audrey Selves, Janick Mouillet-Richard, Sophie Boige, Valérie Emile, Jean-François de Reyniès, Aurélien Laurent-Puig, Pierre |
author_facet | Marisa, Laetitia Blum, Yuna Taieb, Julien Ayadi, Mira Pilati, Camilla Le Malicot, Karine Lepage, Côme Salazar, Ramon Aust, Daniela Duval, Alex Blons, Hélène Taly, Valérie Gentien, David Rapinat, Audrey Selves, Janick Mouillet-Richard, Sophie Boige, Valérie Emile, Jean-François de Reyniès, Aurélien Laurent-Puig, Pierre |
author_sort | Marisa, Laetitia |
collection | PubMed |
description | PURPOSE: The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the transcriptomic ITH of colon cancer and understanding its potential prognostic implications. EXPERIMENTAL DESIGN: We deconvoluted the transcriptomic profiles of 1,779 tumors from the PETACC8 trial and 155 colon cancer cell lines as weighted sums of the four CMSs, using the Weighted In Silico Pathology (WISP) algorithm. We assigned to each tumor and cell line a combination of up to three CMS subtypes with a threshold above 20%. RESULTS: Over 55% of tumors corresponded to mixtures of at least two CMSs, demonstrating pervasive ITH in colon cancer. Of note, ITH was associated with shorter disease-free survival (DFS) and overall survival, [HR, 1.34; 95% confidence interval (CI; 1.12–1.59), 1.40, 95% CI (1.14–1.71), respectively]. Moreover, we uncovered specific combinations of CMS associated with dismal prognosis. In multivariate analysis, ITH represents the third parameter explaining DFS variance, after T and N stages. At a cellular level, combined WISP and single-cell transcriptomic analysis revealed that most colon cancer cell lines are a mixture of cells falling into different CMSs, indicating that ITH may correspond to distinct functional statuses of colon cancer cells. CONCLUSIONS: This study shows that CMS-based transcriptomic ITH is frequent in colon cancer and impacts its prognosis. CMS-based transcriptomic ITH may correspond to distinct functional statuses of colon cancer cells, suggesting plasticity between CMS-related cell populations. Transcriptomic ITH deserves further assessment in the context of personalized medicine. |
format | Online Article Text |
id | pubmed-8974433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-89744332023-01-05 Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer Marisa, Laetitia Blum, Yuna Taieb, Julien Ayadi, Mira Pilati, Camilla Le Malicot, Karine Lepage, Côme Salazar, Ramon Aust, Daniela Duval, Alex Blons, Hélène Taly, Valérie Gentien, David Rapinat, Audrey Selves, Janick Mouillet-Richard, Sophie Boige, Valérie Emile, Jean-François de Reyniès, Aurélien Laurent-Puig, Pierre Clin Cancer Res Precision Medicine and Imaging PURPOSE: The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the transcriptomic ITH of colon cancer and understanding its potential prognostic implications. EXPERIMENTAL DESIGN: We deconvoluted the transcriptomic profiles of 1,779 tumors from the PETACC8 trial and 155 colon cancer cell lines as weighted sums of the four CMSs, using the Weighted In Silico Pathology (WISP) algorithm. We assigned to each tumor and cell line a combination of up to three CMS subtypes with a threshold above 20%. RESULTS: Over 55% of tumors corresponded to mixtures of at least two CMSs, demonstrating pervasive ITH in colon cancer. Of note, ITH was associated with shorter disease-free survival (DFS) and overall survival, [HR, 1.34; 95% confidence interval (CI; 1.12–1.59), 1.40, 95% CI (1.14–1.71), respectively]. Moreover, we uncovered specific combinations of CMS associated with dismal prognosis. In multivariate analysis, ITH represents the third parameter explaining DFS variance, after T and N stages. At a cellular level, combined WISP and single-cell transcriptomic analysis revealed that most colon cancer cell lines are a mixture of cells falling into different CMSs, indicating that ITH may correspond to distinct functional statuses of colon cancer cells. CONCLUSIONS: This study shows that CMS-based transcriptomic ITH is frequent in colon cancer and impacts its prognosis. CMS-based transcriptomic ITH may correspond to distinct functional statuses of colon cancer cells, suggesting plasticity between CMS-related cell populations. Transcriptomic ITH deserves further assessment in the context of personalized medicine. American Association for Cancer Research 2021-06-24 /pmc/articles/PMC8974433/ /pubmed/34168047 http://dx.doi.org/10.1158/1078-0432.CCR-21-0529 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs International 4.0 License. |
spellingShingle | Precision Medicine and Imaging Marisa, Laetitia Blum, Yuna Taieb, Julien Ayadi, Mira Pilati, Camilla Le Malicot, Karine Lepage, Côme Salazar, Ramon Aust, Daniela Duval, Alex Blons, Hélène Taly, Valérie Gentien, David Rapinat, Audrey Selves, Janick Mouillet-Richard, Sophie Boige, Valérie Emile, Jean-François de Reyniès, Aurélien Laurent-Puig, Pierre Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer |
title | Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer |
title_full | Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer |
title_fullStr | Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer |
title_full_unstemmed | Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer |
title_short | Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer |
title_sort | intratumor cms heterogeneity impacts patient prognosis in localized colon cancer |
topic | Precision Medicine and Imaging |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974433/ https://www.ncbi.nlm.nih.gov/pubmed/34168047 http://dx.doi.org/10.1158/1078-0432.CCR-21-0529 |
work_keys_str_mv | AT marisalaetitia intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT blumyuna intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT taiebjulien intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT ayadimira intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT pilaticamilla intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT lemalicotkarine intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT lepagecome intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT salazarramon intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT austdaniela intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT duvalalex intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT blonshelene intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT talyvalerie intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT gentiendavid intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT rapinataudrey intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT selvesjanick intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT mouilletrichardsophie intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT boigevalerie intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT emilejeanfrancois intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT dereyniesaurelien intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer AT laurentpuigpierre intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer |